-
Express significantly prolongs the lives of Asian liver cancer patients, and Keytruda reaches the phase 3 primary clinical endpoint
Time of Update: 2021-10-11
(MSD) announced that in Asian patients with advanced hepatocellular carcinoma (HCC) who have received sorafenib (sorafenib), the heavyweight PD-1 antibody A phase 3 clinical trial of the therapy Keytruda reached the primary endpoint of overall survival (OS) .
-
The control rate of lung cancer can reach 100%!
Time of Update: 2021-10-11
Previously, Kangfang Biological introduced its PD-1/VEGF bi-antibody AK112 combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer at the CSCO meeting, which has attracted widespread attention in the industry.
-
Professor Huang Jing: O+ chemotherapy and O+Y each show "food" power, CheckMate-648 sets two new standards for the first-line esophageal squamous cell carcinoma
Time of Update: 2021-10-11
Professor Huang Jing pointed out that in the first-line treatment of advanced esophageal squamous cell carcinoma based on immune checkpoint inhibitors, CheckMate-648 is by far the largest randomized, global phase III study, including China and other countries from all over the world.
-
FDA's clinical warning analysis on Oncopeptides peptide conjugate Pepaxto
Time of Update: 2021-10-11
On February 26, 2021, the FDA accelerated the approval of PEPAXTO ® (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
-
2021CSCO's wonderful companion diagnosis-based on innovative technology to achieve precise diagnosis and treatment
Time of Update: 2021-10-11
Introduction During the 2021 CSCO General Assembly to "precision | see 'micro' know the, proud 'melt' 'companion diagnostic tumor-themed concert was successfully held on September 28 . Under the l
-
CSCO 2021 Live well to live long!
Time of Update: 2021-10-11
This conference specially invited Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences and Professor Hu Xichun from the Cancer Hospital of Fudan University to co-chair, focusing on real-world research in the field of cancer and the impact of drug selection on the quality of life of advanced breast cancer for further analysis and Explore .
-
Benefits throughout the entire process, guarding new students: Disumab provides another one-dimensional guarantee of efficacy for patients with lung cancer and bone metastases!
Time of Update: 2021-10-11
*Only for medical professionals' reference. Disumab has a rapid onset of action and relieves bone pain. It can be combined with local radiotherapy or targeted drugs to better control lung cancer bo
-
CSCO 2021 PD-1 inhibitor slulizumab + bevacizumab has excellent initial performance for advanced liver cancer
Time of Update: 2021-10-11
The combination of immunotherapy and anti-angiogenesis therapy has made significant progress in the diagnosis and treatment of advanced hepatocellular carcinoma in recent years, successfully breaking through the curative effect bottleneck of previous anti-angiogenic drug monotherapy .
-
[Research] Chinese female scientist Yanjun Qi discovered that mRNA is the key to fighting Alzheimer's disease and cancer!
Time of Update: 2021-10-11
As a part-time faculty member of the Public Health Genomics Center of UVA School of Medicine and UVA School of Data Science, Professor Yanjun Qi worked with biological researchers in different fields of medicine to make model data to better understand the genetic code and its relationship with diseases .
-
2021 CSCO companion diagnosis special session breaks through technical barriers and promotes the clinical implementation of precision diagnosis and treatment
Time of Update: 2021-10-11
From the publication of Dynamic research to the clinical application of Hezhuan, from the exploration of the optimal time point for postoperative MRD monitoring to the exploration of ctDNA combined with low-depth WGS MRD detection scheme, under the guidance of the original spirit, research, technology and clinical workers continue to Break through the technical bottleneck and help promote the full clinical implementation of MRD .
-
Why is cancer deadly?
Time of Update: 2021-10-11
In a new study recently published in the academic journal Developmental Cell, Professor Bilder's team has made a new discovery: a cytokine produced by malignant tumors can cause the blood-brain barrier to leak and accelerate death .
-
Focus on the frontier, target and lead: "Chinese characteristics" liver cancer must be treated like this!
Time of Update: 2021-10-11
, The content focuses on the frontier academic progress of liver cancer treatment, shares the real-world clinical diagnosis and treatment data of lenvatinib, explores and interprets the clinical strategy of translational therapy based on the consensus of Chinese experts on the transformation of liver cancer, and at the same time from the new pattern of interventional combined systemic therapy and the combined action mechanism of target immunity In-depth discussion of perspectives .
-
Baoyuan Pharmaceutical and Cinda Biotech announce the interim data of the phase II trial of taletrectinib for ROS1-positive non-small cell lung cancer at the CSCO 2021 meeting
Time of Update: 2021-10-11
Among 21 patients who were not treated with crizotinib, the confirmed objective response rate (ORR) was 90. 5% (19/21), and the disease control rate (DCR) was 90. 5% (19/21) . Among the 16 patient
-
Express treatment of ovarian cancer and triple-negative breast cancer, innovative ADC therapy entered the clinic
Time of Update: 2021-10-11
▎The content team editor of WuXi AppTec today, ADC Therapeutics announced that its antibody-conjugated drug (ADC) ADCT-901, which targets kidney-associated antigen 1 (KAAG1), has completed the first patient administration in a phase 1 clinical trial.
-
Express first-line treatment of esophageal cancer, two immune combination therapies of BMS are expected to add additional indications
Time of Update: 2021-10-11
▎ WuXi AppTec content team editor September 27, 2021, Bristol Myers Squibb (Bristol Myers Squibb) announced that based on the positive results of phase 3 clinical trials, the US FDA has accepted its PD-1 inhibitor nivolumab, Dual immunotherapy with CTLA-4 inhibitor ipilimumab; and supplementary biological product license application (sBLA) for the combination therapy of nivolumab combined with fluorouracil and platinum-containing chemotherapy for the first-line treatment of advanced unresectable Recurrent, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) .
-
Bispecific monoclonal antibody improves remission rate in patients with myeloma
Time of Update: 2021-10-11
Comment This study proves the efficacy of a new type of bispecific immunotherapy drug for myeloma patients who have received a lot of treatment in the past .
-
2021CSCO report: The current status of Hodgkin's lymphoma treatment illustrates this problem
Time of Update: 2021-10-11
9%, respectively [3]; the Chinese subgroup of the B-HOLISTIC study announced at the European Society of Hematology (EHA) annual meeting in 2021 shows that cHL and RRHL patients The five-year PFS rates of 55.
References: [1]Real-world treatment patterns and clinical outcomes of patients with hodgkin lymphoma in east asia:final results from a b-holistic subgroup.
-
Nature Nanotechnology Academician Comments!
Time of Update: 2021-10-11
After intravenous injection, OPEN can specifically target tumors, efficiently induce IFN secretion in tumors, up-regulate the expression of tumor cells PDL1 and major histocompatibility complex-I (MHC-I), and further promote the uptake of OPEN.
-
Clin Lung Cancer: The safety and efficacy of atezolizumab combined with ipilimumab in the treatment of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes
Time of Update: 2021-10-10
However, the efficacy of the PD-L1 inhibitor atezolizumab combined with the CTLA4 inhibitor ipilimumab in the treatment of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes is unclear .
-
BREAST CANCER RES TR: Asian data released!
Time of Update: 2021-10-10
Myocardial infarctionIn summary, the results of the subgroup analysis of the study showed that the efficacy characteristics of Asian patients with HER2-positive advanced breast cancer who had failed two or more HER2-targeted therapies were consistent with the efficacy characteristics of the entire study population, neratinib + capecita Bin can benefit them significantly, and no new safety issues have been seen .
